Literature DB >> 19049435

Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.

G L Drusano1, W Liu, D L Brown, L B Rice, A Louie.   

Abstract

We previously demonstrated that therapy duration has a differential impact on susceptible and resistant subpopulations of Staphylococcus aureus. What our previous investigation did not address was what would transpire after stopping therapy and whether these events would be different in susceptible and resistant subpopulations. We used the regimen previously demonstrated to amplify resistant subpopulation at day 4-5 (area under the concentration-time curve/minimum inhibitory concentration ratio, 100). Therapy was started in our hollow-fiber infection model on day 0; garenoxacin was administered in 4, 5, or 6 doses (days 3-5). The system was observed until day 13. Four drug doses kept the susceptible population dominant, but with the resistant subpopulation amplifying. Five and 6 doses caused the resistant population to exceed the susceptible population at the end of therapy and for a variable time thereafter. Ultimately, the susceptible population became dominant by day 13. Modeling demonstrated that the resistant isolates grew more slowly and had a higher natural death rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19049435     DOI: 10.1086/595739

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites.

Authors:  Silvie Huijben; William A Nelson; Andrew R Wargo; Derek G Sim; Damien R Drew; Andrew F Read
Journal:  Evolution       Date:  2010-08-19       Impact factor: 3.694

Review 3.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 4.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.

Authors:  Solen Pichereau; Madhulatha Pantrangi; William Couet; Cedric Badiou; Gerard Lina; Sanjay K Shukla; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

6.  Comorbidity in Atopic Dermatitis.

Authors:  Eric L Simpson
Journal:  Curr Dermatol Rep       Date:  2012-03-01

7.  In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.

Authors:  Ganesh Prasad Neupane; Dong-Min Kim; Sung Hun Kim; Bok Kwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

8.  Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.

Authors:  Arnold Louie; Adam Bied; Christine Fregeau; Brian Van Scoy; David Brown; Weiguo Liu; Karen Bush; Anne-Marie Queenan; Brian Morrow; Mohammed Khashab; James B Kahn; Susan Nicholson; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

9.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

10.  New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.

Authors:  Gauri G Rao; Neang S Ly; Curtis E Haas; Samira Garonzik; Alan Forrest; Jurgen B Bulitta; Pamela A Kelchlin; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.